Wednesday, August 16, 2017 10:31:16 AM
2. We all know about that, which is why I didn't post the entire article.
3. If Avant benefits from the sale of OvaDx, then so should ARYC. "Under the settlement, Arrayit retained the right to manufacture the OvaDx test, and Avant retained its right to sell and market OvaDx upon US Food and Drug Administration clearance."
4. As I have said before that 10% could mean an expotential growth over a few years, not a fixed annual percentage. It's sort of silly to expect their business to shrink or stay the same rather than grow with the demand.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM